Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis

Table 1 Clinical and laboratory data of patients studied and controls (mean ± SD)

Parameter	Group I (n = 30)	Group II (n = 15)	Group III (n = 15)	F test	P value
Age (yr)	39.87 ± 6.1	38.20 ± 6.09	39.40 ± 4.56	0.52	P > 0.05 NS
BMI (kg/m2)	29.33 ± 1.92	28.20 ± 3.05	27.73 ± 1.62	1.71	P > 0.05 NS
AST (U/L)	62.40 ± 23.03	39.00 ± 8.7	27.00 ± 5.35	32.63	P1 < 0.0011P2 < 0.0011P3 < 0.0011
ALT (U/L)	42.60 ± 16.31	35.33 ± 7.67	25.67 ± 5.99	16.42	P1 > 0.05 NS P2 < 0.0011P3 < 0.0011
PT (%)	71.87 ± 8.92	61.33 ± 19.22	89.53 ± 5.85	22.04	P1 < 0.0011P2 < 0.0011P3 < 0.0011
Protein (gm/dL)	5.40 ± 1.03	5.00 ± 0.85	7.13 ± 0.88	5.59	P1 > 0.05 NS P2 < 0.0011P3 < 0.0011
Albumin (gm/dL)	2.46 ± 0.47	2.37 ± 0.24	4.35 ± 0.28	33.14	P1 < 0.0011P2 > 0.05 NS P3 < 0.0011
Total bilirubin (mg/dL)	1.30 ± 0.92	1.90 ± 0.97	0.53 ± 0.35	20.85	P1 < 0.001 P2 < 0.001 P3 < 0.001
ALP (U/L)	7.21 ± 3.99	4.30 ± 1.08	2.4 ± 0.82	24.97	P1 > 0.05 NS P2 < 0.0011P3 < 0.001
Urea (mg/dL)	28.2 0± 8.49	28.33 ± 6.45	23.27 ± 4.86	2.65	P1 > 0.05 NS P2 < 0.051P3 < 0.051
Creatinine (mg/dL)	1.10 ± 0.36	0.83 ± 0.34	0.89 ± 0.24	3.77	P1 > 0.05 NS P2 > 0.05 NS P3 > 0.05 NS
Leptin (ng/mL)	34.69 ± 7.69	35.17 ± 1.06	10.69 ± 0.84	107.28	P1 > 0.05 NS P2 < 0.0011P3 < 0.0011
Adiponectin (pg/mL)	131.40 ± 7.91	436.00 ± 9.75	342.40 ± 44.48	374.77	P1 < 0.0011P2 < 0.0011P3 < 0.051

¹Significant. Group I: Patients with hepatic steatosis; Group II: Patients with hepatic fibrosis; Group III: Controls. P1: Comparison between group I and group II; P2: Comparison between group I and group III; P3: Comparison between group II and group III. NS: Non significant; BMI: Body mass index; AST: Aspartate transaminase; ALT: Alanine transaminase; PT: Prothrombin activity; ALP: Alkaline phosphatase.